

Ophthalmology is our singular focus

Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd.

J.P. Morgan Healthcare Conference January 8, 2018



Disclosure Notice

- Information given in presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business
 performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were
 to adversely affect supply capabilities for related final products.
- This presentation includes discussions of certain Santen products marketed in certain markets and compounds in clinical trials, as well as competitors and their products and compounds in clinical trials which are given for illustrative purposes only. Such discussions may include views subject to data interpretation that may or may not be views shared by regulatory authorities in the various regions in which the Company operates.



Agenda



High-Potential Ophthalmology Market







Santen Overall





By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.



To Become a Specialized Pharmaceutical Company with a Global Presence





Strategic Progress Over Last 12 Months

	 Strong, faster-than-market consolidated revenue growth: FY17 H1: +13%¹
Business	 Japan FY17 H1 YoY¹ growth: pharma +7% (now #1 in all 5 major categories²); OTC +25%
growth	 Robust growth continues from overseas businesses in FY17 H1: Asia +24%, EMEA +22%³
	 Established a corporate venture capital fund in U.S. to strengthen strategic investment activities
	DE-089 (<i>Diquas</i>) approved for dry eye in China
Regulatory	 DE-117 (omidenepag isopropyl) met primary endpoint and filed for treatment of glaucoma and ocular hypertension in Japan
news	• Beyond EMEA, new Ikervis approvals received in Singapore, S. Korea, Hong Kong and Taiwan
	 Positive CHMP opinion received for Vekacia for severe vernal keratoconjunctivitis
	 DE-126 (sepetaprost) initiates P2b for glaucoma in U.S. and Japan
Portfolio progress	• DE-128 (InnFocus MicroShunt) for primary open angle glaucoma completes P2/3 study enrollment
progress	DE-122 initiates P2a for wet AMD
New	 DE-127 (atropine sulfate) targeting myopia added to pipeline, now preparing phase 2
pipeline	 DE-114A (epinastine HCI, high dose) for allergic conjunctivitis, phase 3

Santen

7

Santen is a Leading Pharmaceutical Company Specialized in Ophthalmology

Ophthalmology Specialization	Growing Global Market Presence		
 Broad product line-up focused on unmet medical needs Market leader in Japan and Asia 	+6% Annual growth rate of global ophthalmic market from 2013 to 2020		
 Strong market position Japan: 46%, #1 market share China: 13%, #2 market share 	+10.5%	Annual growth rate of Santen revenue from FY2013 to FY2017	
 ✓ Growing productivity and efficiency CAGR +10.0% (JPY billions) 	+29.6%	Santen's overseas sales in FY2017 H1	
EBITDA 33.5 42.5 45.0 42.8 49.0	24 subsidiaries	Asia, EMEA and US	
FY13 FY14 FY15 FY16 FY17 FCST	>60 countries	Global sales	
		,	

Striving to further contribute to ophthalmic treatments and patients around the world

8 Santen's Market Share: FY base ended March 2017 (Japan) and CY2016 base (China)

Source: Copyright © 2017 QuintilesIMS, Calculated based on IMS-JPM 2016-2017 data and IMS-MIDAS 2016 data, reprinted with permission



Santen's Strength

High Customer Satisfaction (CS) based on Specialized Expertise and Strong Business Base

Specialized Expertise

Strong commitment to ophthalmic treatments

· Products and services covering total patient care

Visualizing onset risk, implementing early diagnosis, providing differentiated products, and improving compliance


Addressing unmet needs through all steps in treatment



Santen's Market Share: FY base ended March, 2017 (Japan) and CY2016 base (China, Korea), *Including co-promoted product of Bayer Yakuhin, Ltd. (MAH) Source: Copyright © 2017 QuintilesIMS, Calculated based on IMS-JPM 2016-2017 data and IMS-MIDAS 2016 data, reprinted with permission



Market Leader in Japan- Success in Eylea Sales*




*Eylea is co-promoted with Bayer Yakuhin, Ltd. (MAH)

10 Source: Copyright © 2017 QuintilesIMS. IMS-JPM 2012-17 Santen analysis based on IMS data Reprinted with permission

High Customer Satisfaction and Market Leadership





Covering All Ophthalmic Therapeutic Areas

As the world's leading company focused 100% on ophthalmology, we remain dedicated to answering unmet needs and improving patient of quality of life

Company	Retina	Glaucoma	Dry eye	Infection	Allergy	Cataract
§ anten	√	1	1	1	1	1
Alcon/Novartis	 ✓ 	1	1	1	1	✓
B&L/Valeant	 ✓ 	1	✓	~	✓	✓
Allergan	 ✓ 	1	1	\checkmark	✓	
Pfizer		1				
Genentech	 ✓ 					
Regeneron/Bayer	 ✓ 					
Shire			√			



Expanding Global Partnership Alliances


Santen is working closely with excellent companies, institutes and academia




High Potential Ophthalmology Market



Vision Problems Increasing as World Populations Age



Highest Growth: Asia Region and Glaucoma




*Eylea is co-promoted with Bayer Yakuhin, Ltd. (MAH)

Santen Business Growth




Steady Earnings Growth with Ophthalmology Specialization




Significant JPY appreciation impact in FY16


Continuous growth in Japan – Revenue and OP



Strong Growth in Asia – Revenue and OP




Asia: Continuous Launch of New Products for Regional Needs





Rapid growth in EMEA – Revenue and OP

(JPY billions)



- While building Santen's unique sales organization, the company also continues strong sales of acquired Merck products
- Now focused on *lkervis* market penetration / share expansion going forward




Glaucoma is a Key Growth Driver for Santen

Growing Market	 The market is expected to grow substantially and continuously, boosted by aging populations 			
2x	 With a strong strategic focus, Santen doubled glaucoma revenue to 53 billion JPY in FY16 over 5 years Glaucoma is highly profitable 			
27%	 Santen is focused on glaucoma, already our largest therapeutic area at 27% of revenue 			
8%	 Santen has 8% of global share in glaucoma*, room to grow 			
 Products & Platform Glaucoma business is boosted by tafluprost, acquired MSD products and ne business platforms in EMEA** and Asia 				



Glaucoma is a Key Growth Driver for Santen



New Growth Opportunity: U.S. Market Entry

U.S. Market

- The largest market in the world: 36% of worldwide ophthalmic pharmaceutical market (\$9 billion) 2017*
- Continues to drive the expansion of the worldwide market: +7%*, 2016 YoY

Santen's U.S. Market Entry STRATEGY as a specialized ophthalmic pharmaceutical company				
Differentiated pipeline		To offer new treatments: DE-109,117,126, 128, etc. Becoming profitable		
Flexible strategy		Choosing best strategy to each product:quicklyOwn marketing, co-marketing, licensing out, etc.&		
Stepwise investment		Mitigating business risk on entering new market \bigcirc Maximization of profit		



Pipeline / Product Development Status (1)

	Indication	Region	Status
		US	P2
DE-117 EP2 receptor agonist	Glaucoma / ocular hypertension	Japan	P2b/3 (AYAME pivotal study met primary endpoint), Filed
		Asia	P3. Plan: 2 nd half FY2018 P3 completion
DE-126	Glaucoma /	US	P2b. Plan: Jan~Jun 2018 P2b completion
FP/EP3 dual receptor agonist	ocular hypertension	Japan	
DE-128 InnFocus MicroShunt	Glaucoma	US	P2/3. Plan: Calendar 2018~2019 P2/3 completion, Calendar 2020~2021 launch
		Europe	CE mark granted
		US	Assessing CRL to determine next steps
DE-109	Lhvoitic	Japan	P3
IVT sirolimus	Uveitis	Europe	P3
		Asia	Filed
DE-122 Anti-endoglin antibody	Wet age-related macular degeneration	US	P2a (Completed P1/2) Plan: Jan~Jun 2019 P2a completion



Pipeline / Product Development Status (2)

	Indication	Region	Status
DE-089 Diquas	Dry eye	China	Approved Plan: FY2018 launch
DE-114A epinastine HCI (high dose)	Allergic conjunctivitis	Japan	P3
Cyclokat	Severe keratitis in patients with dry eye	Asia	Approved
lkervis ciclosporin		US	P2
		Others	Filed
Vekacia Verkazia ciclosporin	Vernal kerato- conjunctivitis	Europe	Filed (received positive CHMP opinion)
DE-127 atropine sulfate	Муоріа	Asia	Preparing P2



In Summary, Santen is...

Specialized in ophthalmology

Pursuing unmet medical needs

Building high customer satisfaction with customer-oriented strategy

Enjoying high market share in Japan and continuing strong growth in Asia and EMEA

Steadily growing earnings driven by global new products Preparing for business expansion in the U.S. and other regions

Developing treatments for all stages of glaucoma in our substantial and high-growth franchise

-

Making good progress in key glaucoma area with DE-117, DE-126 and DE-128 *InnFocus MicroShunt*



Continuing and building partnerships with leading companies and institutions worldwide



